Thyroid hormones

The thyroid system of the thyroid hormones T₃ and T₄

Thyroid hormones are any hormones produced and released by the thyroid gland, namely triiodothyronine (T₃) and thyroxine (T₄). They are tyrosine-based hormones that are primarily responsible for regulation of metabolism. T₃ and T₄ are partially composed of iodine, derived from food. ^[2] A deficiency of iodine leads to decreased production of T₃ and T₄, enlarges the thyroid tissue and will cause the disease known as simple goitre. ^[3]

The major form of thyroid hormone in the blood is thyroxine (T₄), whose half-life of around one week ^[4] is longer than that of T₃. ^[5] In humans, the ratio of T₄ to T₃ released into the blood is approximately 14:1. ^[6] T₄ is converted to the active T₃ (three to four times more potent than T₄) within cells by deiodinases (5′-deiodinase). These are further processed by decarboxylation and deiodination to produce iodothyronamine (T₁a) and thyronamine (T₀a). All three isoforms of the deiodinases are selenium-containing enzymes, thus dietary selenium is essential for T₃ production.

The thyroid hormone is one of the factors responsible for the modulation of energy expenditure. This is achieved through several mechanisms, such as mitochondrial biogenesis, adaptive thermogenesis, etc. ^[7]

American chemist Edward Calvin Kendall was responsible for the isolation of thyroxine in 1915. ^[8] In 2020, levothyroxine, a manufactured form of thyroxine, was the second most commonly prescribed medication in the United States, with more than 98 million prescriptions. ^{[9] [10]} Levothyroxine is on the World Health Organization's List of Essential Medicines. ^[11]

Function

The thyroid hormones act on nearly every cell in the body. It acts to increase the basal metabolic rate, affect protein synthesis, help regulate long bone growth (synergy with growth hormone) and neural maturation, and increase the body's sensitivity to catecholamines (such as adrenaline) by permissiveness. ^[12] The thyroid hormones are essential to proper development and differentiation of all cells of the human body. These hormones also regulate protein, fat, and carbohydrate metabolism, affecting how human cells use energetic compounds. They also stimulate vitamin metabolism. Numerous physiological and pathological stimuli influence thyroid hormone synthesis.

Thyroid hormone leads to heat generation in humans. However, the thyronamines function via some unknown mechanism to inhibit neuronal activity; this plays an important role in the hibernation cycles of mammals and the moulting behaviour of birds. One effect of administering the thyronamines is a severe drop in body temperature.

Medical use

Both T₃ and T₄ are used to treat thyroid hormone deficiency (hypothyroidism). They are both absorbed well by the stomach, so can be given orally. Levothyroxine is the chemical name of the manufactured version of T₄, which is metabolised more slowly than T₃ and hence usually only needs once-daily administration. Natural desiccated thyroid hormones are derived from pig thyroid glands, and are a "natural" hypothyroid treatment containing 20% T₃ and traces of T₂, T₁ and calcitonin. Also available are synthetic combinations of T₃/T₄ in different ratios (such as liotrix) and pure-T₃ medications (INN: liothyronine). Levothyroxine Sodium is usually the first course of treatment tried. Some patients feel they do better on desiccated thyroid hormones; however, this is based on anecdotal evidence and clinical trials have not shown any benefit over the biosynthetic forms. ^[13] Thyroid tablets are reported to have different effects, which can be attributed to the difference in torsional angles surrounding the reactive site of the molecule. ^[14]

Thyronamines have no medical usages yet, though their use has been proposed for controlled induction of hypothermia, which causes the brain to enter a protective cycle, useful in preventing damage during ischemic shock.

Synthetic thyroxine was first successfully produced by Charles Robert Harington and George Barger in 1926.

Formulations

Structure of (S)-thyroxine (T₄)

(S)-triiodothyronine (T₃, also called liothyronine)

Most people are treated with levothyroxine, or a similar synthetic thyroid hormone. ^{[15] [16] [17]} Different polymorphs of the compound have different solubilities and potencies. ^[18] Additionally, natural thyroid hormone supplements from the dried thyroids of animals are still available. ^{[17] [19] [20]} Levothyroxine contains T₄ only and is therefore largely ineffective for patients unable to convert T₄ to T₃. ^[21] These patients may choose to take natural thyroid hormone, as it contains a mixture of T₄ and T₃, ^{[17] [22] [23] [24] [25]} or alternatively supplement with a synthetic T₃ treatment. ^[26] In these cases, synthetic liothyronine is preferred due to the potential differences between the natural thyroid products. Some studies show that the mixed therapy is beneficial to all patients, but the addition of lyothyronine contains additional side effects and the medication should be evaluated on an individual basis. ^[27] Some natural thyroid hormone brands are FDA approved, but some are not. ^{[28] [29] [30]} Thyroid hormones are generally well tolerated. ^[16] Thyroid hormones are usually not dangerous for pregnant women or nursing mothers, but should be given under a doctor's supervision. In fact, if a woman who is hypothyroid is left untreated, her baby is at a higher risk for birth defects. When pregnant, a woman with a low-functioning thyroid will also need to increase her dosage of thyroid hormone. ^[16] One exception is that thyroid hormones may aggravate heart conditions, especially in older patients; therefore, doctors may start these patients on a lower dose and work up to a larger one to avoid risk of heart attack. ^[17]

Thyroid metabolism

Central

Synthesis of the thyroid hormones, as seen on an individual thyroid follicular cell:
- Thyroglobulin is synthesized in the rough endoplasmic reticulum and follows the secretory pathway to enter the colloid in the lumen of the thyroid follicle by exocytosis.
- Meanwhile, a sodium-iodide (Na/I) symporter pumps iodide (I ) actively into the cell, which previously has crossed the endothelium by largely unknown mechanisms.
- This iodide enters the follicular lumen from the cytoplasm by the transporter pendrin, in a purportedly passive manner.
- In the colloid, iodide (I ) is oxidized to iodine (I ) by an enzyme called thyroid peroxidase.
- Iodine (I ) is very reactive and iodinates the thyroglobulin at tyrosyl residues in its protein chain (in total containing approximately 120 tyrosyl residues).
- In conjugation, adjacent tyrosyl residues are paired together.
- Thyroglobulin re-enters the follicular cell by endocytosis.
- Proteolysis by various proteases liberates thyroxine and triiodothyronine molecules
- Efflux of thyroxine and triiodothyronine from follicular cells, which appears to be largely through monocarboxylate transporter (MCT) 8 and 10, and entry into the blood.

Thyroid hormones (T₄ and T₃) are produced by the follicular cells of the thyroid gland and are regulated by TSH made by the thyrotropes of the anterior pituitary gland. The effects of T₄ in vivo are mediated via T₃ (T₄ is converted to T₃ in target tissues). T₃ is three to five times more active than T₄.

T₄, Thyroxine (3,5,3′,5′-tetraiodothyronine), is produced by follicular cells of the thyroid gland. It is produced from the precursor thyroglobulin (this is not the same as thyroxine-binding globulin (TBG)), which is cleaved by enzymes to produce active T₄. ^[34]

The steps in this process are as follows: ^[31]

1. The Na⁺/I⁻ symporter transports two sodium ions across the basement membrane of the follicular cells along with an iodide ion. This is a secondary active transporter that utilises the concentration gradient of Na⁺ to move I⁻ against its concentration gradient.
2. I⁻ is moved across the apical membrane into the colloid of the follicle by pendrin.
3. Thyroperoxidase oxidizes two I⁻ to form I₂. Iodide is non-reactive, and only the more reactive iodine is required for the next step.
4. The thyroperoxidase iodinates the tyrosyl residues of the thyroglobulin within the colloid. The thyroglobulin was synthesised in the ER of the follicular cell and secreted into the colloid.
5. Iodinated Thyroglobulin binds megalin for endocytosis back into cell.
6. Thyroid-stimulating hormone (TSH) released from the anterior pituitary (also known as the adenohypophysis) binds the TSH receptor (a G_s protein-coupled receptor) on the basolateral membrane of the cell and stimulates the endocytosis of the colloid.
7. The endocytosed vesicles fuse with the lysosomes of the follicular cell. The lysosomal enzymes cleave the T₄ from the iodinated thyroglobulin.
8. The thyroid hormones cross the follicular cell membrane towards the blood vessels by an unknown mechanism. ^[31] Text books have stated that diffusion is the main means of transport, ^[35] but recent studies indicate that monocarboxylate transporter (MCT) 8 and 10 play major roles in the efflux of the thyroid hormones from the thyroid cells. ^{[32] [33]}

Thyroglobulin (Tg) is a 660  kDa, dimeric protein produced by the follicular cells of the thyroid and used entirely within the thyroid gland. ^[36] Thyroxine is produced by attaching iodine atoms to the ring structures of this protein's tyrosine residues; thyroxine (T₄) contains four iodine atoms, while triiodothyronine (T₃), otherwise identical to T₄, has one less iodine atom per molecule. ^[37] The thyroglobulin protein accounts for approximately half of the protein content of the thyroid gland. ^[38] Each thyroglobulin molecule contains approximately 100–120 tyrosine residues, a small number of which (<20) are subject to iodination catalysed by thyroperoxidase. ^[39] The same enzyme then catalyses "coupling" of one modified tyrosine with another, via a free-radical-mediated reaction, and when these iodinated bicyclic molecules are released by hydrolysis of the protein, T₃ and T₄ are the result. ^[40] Therefore, each thyroglobulin protein molecule ultimately yields very small amounts of thyroid hormone (experimentally observed to be on the order of 5–6 molecules of either T₄ or T₃ per original molecule of thyroglobulin). ^[39]

More specifically, the monatomic anionic form of iodine, iodide (I^—), is actively absorbed from the bloodstream by a process called iodide trapping. ^[41] In this process, sodium is cotransported with iodide from the basolateral side of the membrane into the cell,^{[ clarification needed ]} and then concentrated in the thyroid follicles to about thirty times its concentration in the blood. ^{[42] [43]} Then, in the first reaction catalysed by the enzyme thyroperoxidase, tyrosine residues in the protein thyroglobulin are iodinated on their phenol rings, at one or both of the positions ortho to the phenolic hydroxyl group, yielding monoiodotyrosine (MIT) and diiodotyrosine (DIT), respectively. This introduces 1–2 atoms of the element iodine, covalently bound, per tyrosine residue. ^[44] The further coupling together of two fully iodinated tyrosine residues, also catalysed by thyroperoxidase, yields the peptidic (still peptide-bound) precursor of thyroxine, and coupling one molecule of MIT and one molecule of DIT yields the comparable precursor of triiodothyronine: ^[45]

• peptidic MIT + peptidic DIT → peptidic triiodothyronine (eventually released as triiodothyronine, T₃)
• 2 peptidic DITs → peptidic thyroxine (eventually released as thyroxine, T₄)

(Coupling of DIT to MIT in the opposite order yields a substance, r-T₃, which is biologically inactive. ^{[46] [47] [ relevant? ]}) Hydrolysis (cleavage to individual amino acids) of the modified protein by proteases then liberates T₃ and T₄, as well as the non-coupled tyrosine derivatives MIT and DIT. ^{[48] [49]} The hormones T₄ and T₃ are the biologically active agents central to metabolic regulation. ^[50]

Peripheral

Thyroxine is believed to be a prohormone and a reservoir for the most active and main thyroid hormone T₃. ^[51] T₄ is converted as required in the tissues by iodothyronine deiodinase. ^[52] Deficiency of deiodinase can mimic hypothyroidism due to iodine deficiency. ^[53] T₃ is more active than T₄, ^[54] though it is present in less quantity than T₄.

Initiation of production in fetuses

Thyrotropin-releasing hormone (TRH) is released from hypothalamus by 6 – 8 weeks, and thyroid-stimulating hormone (TSH) secretion from fetal pituitary is evident by 12 weeks of gestation, and fetal production of thyroxine (T₄) reaches a clinically significant level at 18–20 weeks. ^[55] Fetal triiodothyronine (T₃) remains low (less than 15 ng/dL) until 30 weeks of gestation, and increases to 50 ng/dL at term. ^[55] Fetal self-sufficiency of thyroid hormones protects the fetus against e.g. brain development abnormalities caused by maternal hypothyroidism. ^[56]

Iodine deficiency

If there is a deficiency of dietary iodine, the thyroid will not be able to make thyroid hormones. ^[57] The lack of thyroid hormones will lead to decreased negative feedback on the pituitary, leading to increased production of thyroid-stimulating hormone, which causes the thyroid to enlarge (the resulting medical condition is called endemic colloid goitre; see goitre). ^[58] This has the effect of increasing the thyroid's ability to trap more iodide, compensating for the iodine deficiency and allowing it to produce adequate amounts of thyroid hormone. ^[59]

Circulation and transport

Plasma transport

Most of the thyroid hormone circulating in the blood is bound to transport proteins, and only a very small fraction is unbound and biologically active. Therefore, measuring concentrations of free thyroid hormones is important for diagnosis, while measuring total levels can be misleading.

Thyroid hormone in the blood is usually distributed as follows:^{[ citation needed ]}

Type	Percent
bound to thyroxine-binding globulin (TBG)	70%
bound to transthyretin or "thyroxine-binding prealbumin" (TTR or TBPA)	10–15%
albumin	15–20%
unbound T4 (fT4)	0.03%
unbound T3 (fT3)	0.3%

Despite being lipophilic, T₃ and T₄ cross the cell membrane via carrier-mediated transport, which is ATP-dependent. ^[60]

T₁a and T₀a are positively charged and do not cross the membrane; they are believed to function via the trace amine-associated receptor TAAR1 (TAR1, TA1), a G-protein-coupled receptor located in the cytoplasm.

Another critical diagnostic tool is measurement of the amount of thyroid-stimulating hormone (TSH) that is present.

Membrane transport

Contrary to common belief, thyroid hormones cannot traverse cell membranes in a passive manner like other lipophilic substances. The iodine in o-position makes the phenolic OH-group more acidic, resulting in a negative charge at physiological pH. However, at least 10 different active, energy-dependent and genetically regulated iodothyronine transporters have been identified in humans. They guarantee that intracellular levels of thyroid hormones are higher than in blood plasma or interstitial fluids. ^[61]

Intracellular transport

Little is known about intracellular kinetics of thyroid hormones. However, recently it could be demonstrated that the crystallin CRYM binds 3,5,3′-triiodothyronine in vivo. ^[62]

Mechanism of action

Main article: Thyroid hormone receptor

The thyroid hormones function via a well-studied set of nuclear receptors, termed the thyroid hormone receptors. These receptors, together with corepressor molecules, bind DNA regions called thyroid hormone response elements (TREs) near genes. This receptor-corepressor-DNA complex can block gene transcription. Triiodothyronine (T₃), which is the active form of thyroxine (T₄), goes on to bind to receptors. The deiodinase catalyzed reaction removes an iodine atom from the 5′ position of the outer aromatic ring of thyroxine's (T₄) structure. ^[63] When triiodothyronine (T₃) binds a receptor, it induces a conformational change in the receptor, displacing the corepressor from the complex. This leads to recruitment of coactivator proteins and RNA polymerase, activating transcription of the gene. ^[64] Although this general functional model has considerable experimental support, there remain many open questions. ^[65]

More recently genetic evidence has been obtained for a second mechanism of thyroid hormone action involving one of the same nuclear receptors, TRβ, acting rapidly in the cytoplasm through the PI3K. ^{[66] [67]} This mechanism is conserved in all mammals but not fish or amphibians, and regulates brain development ^[66] and adult metabolism. ^[67] The mechanism itself parallels the actions of the nuclear receptor in the nucleus: in the absence of hormone, TRβ binds to PI3K and inhibits its activity, but when hormone binds the complex dissociates, PI3K activity increases, and the hormone bound receptor diffuses into the nucleus. ^[66]

Thyroxine, iodine and apoptosis

Thyroxine and iodine stimulate the apoptosis of the cells of the larval gills, tail and fins in amphibian metamorphosis, and stimulate the evolution of their nervous system transforming the aquatic, vegetarian tadpole into the terrestrial, carnivorous frog. In fact, amphibian frog Xenopus laevis serves as an ideal model system for the study of the mechanisms of apoptosis. ^{[68] [69] [70] [71]}

Effects of triiodothyronine

Effects of triiodothyronine (T₃) which is the metabolically active form:

• Increases cardiac output
• Increases heart rate
• Increases ventilation rate
• Increases basal metabolic rate
• Potentiates the effects of catecholamines (i.e. increases sympathetic activity)
• Potentiates brain development
• Thickens endometrium in females
• Increases catabolism of proteins and carbohydrates ^[72]

Measurement

Further information: Thyroid function tests

Triiodothyronine (T₃) and thyroxine (T₄) can be measured as free T₃ and free T₄, which are indicators of their activities in the body. ^[73] They can also be measured as total T₃ and total T₄, which depend on the amount that is bound to thyroxine-binding globulin (TBG). ^[73] A related parameter is the free thyroxine index, which is total T₄ multiplied by thyroid hormone uptake, which, in turn, is a measure of the unbound TBG. ^[74] Additionally, thyroid disorders can be detected prenatally using advanced imaging techniques and testing fetal hormone levels. ^[75]

Related diseases

Both excess and deficiency of thyroxine can cause disorders.

• Hyperthyroidism (an example is Graves' disease) is the clinical syndrome caused by an excess of circulating free thyroxine, free triiodothyronine, or both. It is a common disorder that affects approximately 2% of women and 0.2% of men. Thyrotoxicosis is often used interchangeably with hyperthyroidism, but there are subtle differences. Although thyrotoxicosis also refers to an increase in circulating thyroid hormones, it can be caused by the intake of thyroxine tablets or by an over-active thyroid, whereas hyperthyroidism refers solely to an over-active thyroid.
• Hypothyroidism (an example is Hashimoto's thyroiditis) is the case where there is a deficiency of thyroxine, triiodothyronine, or both.
• Clinical depression can sometimes be caused by hypothyroidism. ^[76] Some research ^[77] has shown that T₃ is found in the junctions of synapses, and regulates the amounts and activity of serotonin, norepinephrine, and γ-aminobutyric acid (GABA) in the brain.
• Hair loss can sometimes be attributed to a malfunction of T₃ and T₄. Normal hair growth cycle may be affected disrupting the hair growth.
• Both thyroid excess and deficiency can cause cardiovascular disorders or make preexisting conditions worse. ^[78] The link between excess and deficiency of thyroid hormone on conditions like arrhythmias, heart failure, and atherosclerotic vascular diseases, have been established for nearly 200 years. ^{[79] [78]}
• Abnormal thyroid function—hypo- and hyperthyroidism—can manifest as myopathy with symptoms of exercise-induced muscle fatigue, cramping, muscle pain and may include proximal weakness or muscle hypertrophy (particularly of the calves). ^{[80] [81]} Prolonged hypo- and hyperthyroid myopathy leads to atrophy of type II (fast-twitch/glycolytic) muscle fibres, and a predominance of type I (slow-twitch/oxidative) muscle fibres. ^{[81] [82] [83]} Muscle biopsy shows abnormal muscle glycogen: high accumulation in hypothyroidism and low accumulation in hyperthyroidism. ^{[82] [84] [85]} Myopathy associated with hypothyroidism includes Kocher-Debre-Semelaigne syndrome (childhood-onset), Hoffman syndrome (adult-onset), myasthenic syndrome, and atrophic form. ^[84] Myopathy associated with hyperthyroidism includes thyrotoxic myopathy, thyrotoxic periodic paralysis, and Graves' ophthalmopathy. ^[80] In Graves' ophthalmopathy, the proptosis is secondary to extraocular muscle (EOM) enlargement and gross expansion of orbital fat. ^[86]

Preterm births can suffer neurodevelopmental disorders due to lack of maternal thyroid hormones, at a time when their own thyroid is unable to meet their postnatal needs. ^[87] Also in normal pregnancies, adequate levels of maternal thyroid hormone are vital in order to ensure thyroid hormone availability for the foetus and its developing brain. ^[88] Congenital hypothyroidism occurs in every 1 in 1600–3400 newborns with most being born asymptomatic and developing related symptoms weeks after birth. ^[89]

Anti-thyroid drugs

Iodine uptake against a concentration gradient is mediated by a sodium–iodine symporter and is linked to a sodium-potassium ATPase. Perchlorate and thiocyanate are drugs that can compete with iodine at this point. Compounds such as goitrin, carbimazole, methimazole, propylthiouracil can reduce thyroid hormone production by interfering with iodine oxidation. ^[90]

References

1. References used in image are found in image article in Commons:Commons:File:Thyroid system.png#References.
2. Sargis, Robert M. (21 October 2019). "How Your Thyroid Works". endocrineweb.com. Retrieved 20 May 2023.
3. Ijaz Ahsan (1997). Textbook of Surgery. CRC Press. p. 376. ISBN   9789057021398.
4. "How long does thyroxine stay in your system?". Drugs.com. Retrieved 6 August 2022.
5. Irizarry L (23 April 2014). "Thyroid Hormone Toxicity". Medscape. WedMD LLC. Retrieved 2 May 2014.
6. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R (April 1990). "Thyroidal and peripheral production of 3,5,3′-triiodothyronine in humans by multicompartmental analysis". The American Journal of Physiology. 258 (4 Pt 1): E715–E726. doi:10.1152/ajpendo.1990.258.4.E715. PMID   2333963.
7. Tran, Le Trung; Park, Sohee; Kim, Seul Ki; Lee, Jin Sun; Kim, Ki Woo; Kwon, Obin (April 2022). "Hypothalamic control of energy expenditure and thermogenesis". Experimental & Molecular Medicine. 54 (4): 358–369. doi:10.1038/s12276-022-00741-z. ISSN   2092-6413. PMC   9076616 . PMID   35301430.
8. "1926 Edward C Kendall". American Society for Biochemistry and Molecular Biology. Archived from the original on 19 March 2012. Retrieved 4 July 2011.
9. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
10. "Levothyroxine - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
11. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
12. Shahid, Muhammad A.; Ashraf, Muhammad A.; Sharma, Sandeep (2022), "Physiology, Thyroid Hormone", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   29763182 , retrieved 18 August 2022
13. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L (July 2006). "Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials". The Journal of Clinical Endocrinology and Metabolism. 91 (7): 2592–2599. doi: 10.1210/jc.2006-0448 . PMID   16670166.
14. Schweizer U, Steegborn C (October 2015). "Thyroid hormones--From Crystal Packing to Activity to Reactivity". Angewandte Chemie. 54 (44): 12856–12858. doi:10.1002/anie.201506919. PMID   26358899.
15. Robert Lloyd Segal, MD Endocrinologist
16. "preferred thyroid hormone --Levothyroxine Sodium (Synthroid, Levoxyl, Levothroid, Unithroid)". MedicineNet.com. Retrieved 27 March 2009.
17. "Hypothyroidism Causes, Symptoms, Diagnosis, Treatment Information Produced by Medical Doctors". MedicineNet.com. Retrieved 27 March 2009.
18. Mondal S, Mugesh G (September 2015). "Structure Elucidation and Characterization of Different Thyroxine Polymorphs". Angewandte Chemie. 54 (37): 10833–10837. doi:10.1002/anie.201505281. PMID   26213168.
19. Cooper DS (May 1989). "Thyroid hormone treatment: new insights into an old therapy". JAMA. 261 (18): 2694–2695. doi:10.1001/jama.1989.03420180118042. PMID   2709547.
20. Clyde PW, Harari AE, Mohamed Shakir KM (2004). "Synthetic Thyroxine vs Desiccated Thyroid -Reply (citing Cooper, DS, above)". JAMA: The Journal of the American Medical Association. 291 (12): 1445. doi:10.1001/jama.291.12.1445-b.
21. Wiersinga WM (2001). "Thyroid hormone replacement therapy". Hormone Research. 56 (Suppl 1): 74–81. doi:10.1159/000048140. PMID   11786691. S2CID   46756918.
22. "Consequences of Not Taking Thyroid Medications - Implications of Failing to Take Prescription Thyroid Drugs" Archived 16 February 2009 at the Wayback Machine , Retrieved on 27 March 2009
23. "Armour Thyroid", Retrieved on 1 April 2009
24. "Nature-Throid", Retrieved on 1 April 2009
25. "Armour Thyroid Shortages Worsening: What Can Thyroid Patients Do?" Archived 3 March 2009 at the Wayback Machine , Retrieved on 27 March 2009
26. Liothyronine
27. Escobar-Morreale HF, Botella-Carretero JI, Morreale de Escobar G (January 2015). "Treatment of hypothyroidism with levothyroxine or a combination of levothyroxine plus L-triiodothyronine". Best Practice & Research. Clinical Endocrinology & Metabolism. 29 (1): 57–75. doi:10.1016/j.beem.2014.10.004. hdl: 10261/124621 . PMID   25617173.
28. "Thyroid Information" Archived 27 February 2012 at the Wayback Machine , Retrieved on 27 March 2009
29. Eliason BC, Doenier JA, Nuhlicek DN (March 1994). "Desiccated thyroid in a nutritional supplement". The Journal of Family Practice. 38 (3): 287–288. PMID   8126411.
30. "Nature-Throid" Archived 15 February 2009 at the Wayback Machine , Retrieved on 1 April 2009
31. Chapter 49, "Synthesis of Thyroid Hormones" in: Walter F. Boron; Emile L. Boulpaep (2012). Medical Physiology (2nd ed.). Elsevier/Saunders. ISBN   9781437717532.^{[ page needed ]}
32. Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH, Visser TJ (June 2008). "Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10". Molecular Endocrinology. 22 (6): 1357–1369. doi:10.1210/me.2007-0112. PMC   5419535 . PMID   18337592.
33. Brix K, Führer D, Biebermann H (August 2011). "Molecules important for thyroid hormone synthesis and action - known facts and future perspectives". Thyroid Research. 4 (Suppl. 1): S9. doi: 10.1186/1756-6614-4-S1-S9 . PMC   3155115 . PMID   21835056.
34. "The thyroid gland". Endocrinology: An Integrated Approach. BIOS Scientific Publishers. 28 March 2024.
35. Human Anatomy & Physiology, Sixth Edition . Benjamin Cummings. 2 May 2003. ISBN   978-0805354621.
36. Dabbs DJ (2019). Diagnostic Immunohistochemistry. Elsevier. pp. 345–389.
37. Izumi, M.; Larsen, P. Reed (1 June 1977). "Triiodothyronine, Thyroxine, and Iodine in Purified Thyroglobulin from Patients with Graves' Disease". Journal of Clinical Investigation. 59 (6): 1105–1112. doi:10.1172/JCI108734. ISSN   0021-9738. PMC   372323 . PMID   577211.
38. Zhang, Xiaohan; Malik, Bhoomanyu; Young, Crystal; Zhang, Hao; Larkin, Dennis; Liao, Xiao-Hui; Refetoff, Samuel; Liu, Ming; Arvan, Peter (23 May 2022). "Maintaining the thyroid gland in mutant thyroglobulin-induced hypothyroidism requires thyroid cell proliferation that must continue in adulthood". The Journal of Biological Chemistry. 298 (7): 102066. doi: 10.1016/j.jbc.2022.102066 . ISSN   1083-351X. PMC   9213252 . PMID   35618019.
39. Boron, W.F. (2003). Medical Physiology: A Cellular And Molecular Approach. Elsevier/Saunders. ISBN   1416023283.
40. Marmelstein, Alan M.; Lobba, Marco J.; Mogilevsky, Casey S.; Maza, Johnathan C.; Brauer, Daniel D.; Francis, Matthew B. (18 March 2020). "Tyrosinase-Mediated Oxidative Coupling of Tyrosine Tags on Peptides and Proteins". Journal of the American Chemical Society. 142 (11): 5078–5086. doi:10.1021/jacs.9b12002. ISSN   1520-5126. PMID   32093466.
41. Ahad F, Ganie SA (January 2010). "Iodine, Iodine metabolism and Iodine deficiency disorders revisited". Indian Journal of Endocrinology and Metabolism. 14 (1): 13–17. PMC   3063534 . PMID   21448409.
42. Nilsson, M. (2001). "Iodide handling by the thyroid epithelial cell". Experimental and Clinical Endocrinology & Diabetes. 109 (1): 13–17. doi:10.1055/s-2001-11014. ISSN   0947-7349. PMID   11573132. S2CID   37723663.
43. Martín, Mariano; Salleron, Lisa; Peyret, Victoria; Geysels, Romina Celeste; Darrouzet, Elisabeth; Lindenthal, Sabine; Bernal Barquero, Carlos Eduardo; Masini-Repiso, Ana María; Pourcher, Thierry; Nicola, Juan Pablo (1 July 2021). "The PDZ protein SCRIB regulates sodium/iodide symporter (NIS) expression at the basolateral plasma membrane". FASEB Journal. 35 (8): e21681. doi: 10.1096/fj.202100303R . ISSN   1530-6860. PMID   34196428. S2CID   235698589.
44. Ahad, Farhana; Ganie, Shaiq A. (2010). "Iodine, Iodine metabolism and Iodine deficiency disorders revisited". Indian Journal of Endocrinology and Metabolism. 14 (1): 13–17. ISSN   2230-8210. PMC   3063534 . PMID   21448409.
45. den Hartog, M. T.; Sijmons, C. C.; Bakker, O.; Ris-Stalpers, C.; de Vijlder, J. J. (1995). "Importance of the content and localization of tyrosine residues for thyroxine formation within the N-terminal part of human thyroglobulin". European Journal of Endocrinology. 132 (5): 611–617. doi:10.1530/eje.0.1320611. ISSN   0804-4643. PMID   7749504.
46. Rousset, Bernard; Dupuy, Corinne; Miot, Françoise; Dumont, Jacques (2000), Feingold, Kenneth R.; Anawalt, Bradley; Boyce, Alison; Chrousos, George (eds.), "Chapter 2 Thyroid Hormone Synthesis And Secretion", Endotext, South Dartmouth (MA): MDText.com, Inc., PMID   25905405 , retrieved 23 November 2022
47. Li, Dongdong; Zhang, Yuping; Fan, Zhiying; Chen, Jie; Yu, Jihong (1 November 2015). "Coupling of chromophores with exactly opposite luminescence behaviours in mesostructured organosilicas for high-efficiency multicolour emission". Chemical Science. 6 (11): 6097–6101. doi:10.1039/c5sc02044a. ISSN   2041-6520. PMC   6054107 . PMID   30090223.
48. Darragh, Alison J.; Moughan, Paul J. (2005). "The effect of hydrolysis time on amino acid analysis". Journal of AOAC International. 88 (3): 888–893. doi: 10.1093/jaoac/88.3.888 . ISSN   1060-3271. PMID   16001867.
49. Jim, Susan; Jones, Vicky; Copley, Mark S.; Ambrose, Stanley H.; Evershed, Richard P. (2003). "Effects of hydrolysis on the delta13C values of individual amino acids derived from polypeptides and proteins". Rapid Communications in Mass Spectrometry. 17 (20): 2283–2289. doi:10.1002/rcm.1177. ISSN   0951-4198. PMID   14558127.
50. Brent, Gregory A. (4 September 2012). "Mechanisms of thyroid hormone action". The Journal of Clinical Investigation. 122 (9): 3035–3043. doi:10.1172/JCI60047. ISSN   0021-9738. PMC   3433956 . PMID   22945636.
51. Kansagra SM, McCudden CR, Willis MS (June 2010). "The Challenges and Complexities of Thyroid Hormone Replacement". Laboratory Medicine. 41 (6): 338–348. doi: 10.1309/LMB39TH2FZGNDGIM .
52. St Germain DL, Galton VA, Hernandez A (March 2009). "Minireview: Defining the roles of the iodothyronine deiodinases: current concepts and challenges". Endocrinology. 150 (3): 1097–1107. doi:10.1210/en.2008-1588. PMC   2654746 . PMID   19179439.
53. Wass JA, Stewart PM, eds. (2011). Oxford Textbook of Endocrinology and Diabetes (2nd ed.). Oxford: Oxford University Press. p. 565. ISBN   978-0-19-923529-2.
54. Wass JA, Stewart PM, eds. (2011). Oxford Textbook of Endocrinology and diabetes (2nd ed.). Oxford: Oxford University Press. p. 18. ISBN   978-0-19-923529-2.
55. Eugster EA, Pescovitz OH (2004). Pediatric endocrinology: mechanisms, manifestations and management. Hagerstwon, MD: Lippincott Williams & Wilkins. pp. 493 (Table 33-3). ISBN   978-0-7817-4059-3.
56. Zoeller RT (April 2003). "Transplacental thyroxine and fetal brain development". The Journal of Clinical Investigation. 111 (7): 954–957. doi:10.1172/JCI18236. PMC   152596 . PMID   12671044.
57. Zimmermann, Michael B.; Boelaert, Kristien (12 January 2015). "Iodine deficiency and thyroid disorders". The Lancet. Diabetes & Endocrinology. 3 (4): 286–295. doi:10.1016/S2213-8587(14)70225-6. ISSN   2213-8595. PMID   25591468.
58. McPherson, Richard A.; Pincus, Matthew R. (5 April 2017). Henry's clinical diagnosis and management by laboratory methods. McPherson, Richard A.,, Pincus, Matthew R. (23rd ed.). St. Louis, Mo. ISBN   9780323413152. OCLC   949280055.
59. Bähre, M.; Hilgers, R.; Lindemann, C.; Emrich, D. (1987). "Physiological aspects of the thyroid trapping function and its suppression in iodine deficiency using 99mTc pertechnetate". Acta Endocrinologica. 115 (2): 175–182. doi:10.1530/acta.0.1150175. ISSN   0001-5598. PMID   3037834.
60. Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ (August 2001). "Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability". Endocrine Reviews. 22 (4): 451–476. doi: 10.1210/edrv.22.4.0435 . hdl: 1765/9707 . PMID   11493579.
61. Dietrich JW, Brisseau K, Boehm BO (August 2008). "[Absorption, transport and bio-availability of iodothyronines]". Deutsche Medizinische Wochenschrift. 133 (31–32): 1644–1648. doi:10.1055/s-0028-1082780. PMID   18651367.
62. Suzuki S, Suzuki N, Mori J, Oshima A, Usami S, Hashizume K (April 2007). "micro-Crystallin as an intracellular 3,5,3′-triiodothyronine holder in vivo". Molecular Endocrinology. 21 (4): 885–894. doi: 10.1210/me.2006-0403 . PMID   17264173.
63. Mullur R, Liu YY, Brent GA (April 2014). "Thyroid hormone regulation of metabolism". Physiological Reviews. 94 (2): 355–382. doi:10.1152/physrev.00030.2013. PMC   4044302 . PMID   24692351.
64. Wu Y, Koenig RJ (August 2000). "Gene regulation by thyroid hormone". Trends in Endocrinology and Metabolism. 11 (6): 207–211. doi:10.1016/s1043-2760(00)00263-0. PMID   10878749. S2CID   44602986.
65. Ayers S, Switnicki MP, Angajala A, Lammel J, Arumanayagam AS, Webb P (2014). "Genome-wide binding patterns of thyroid hormone receptor beta". PLOS ONE. 9 (2): e81186. Bibcode:2014PLoSO...981186A. doi: 10.1371/journal.pone.0081186 . PMC   3928038 . PMID   24558356.
66. Martin NP, Marron Fernandez de Velasco E, Mizuno F, Scappini EL, Gloss B, Erxleben C, et al. (September 2014). "A rapid cytoplasmic mechanism for PI3-kinase regulation by the nuclear thyroid hormone receptor, TRβ, and genetic evidence for its role in the maturation of mouse hippocampal synapses in vivo". Endocrinology. 155 (9): 3713–3724. doi:10.1210/en.2013-2058. PMC   4138568 . PMID   24932806.
67. Hönes GS, Rakov H, Logan J, Liao XH, Werbenko E, Pollard AS, et al. (December 2017). "Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo". Proceedings of the National Academy of Sciences of the United States of America. 114 (52): E11323–E11332. Bibcode:2017PNAS..11411323H. doi: 10.1073/pnas.1706801115 . PMC   5748168 . PMID   29229863.
68. Jewhurst K, Levin M, McLaughlin KA (2014). "Optogenetic Control of Apoptosis in Targeted Tissues of Xenopus laevis Embryos". Journal of Cell Death. 7: 25–31. doi:10.4137/JCD.S18368. PMC   4213186 . PMID   25374461.
69. Venturi, Sebastiano (2011). "Evolutionary Significance of Iodine". Current Chemical Biology. 5 (3): 155–162. doi:10.2174/187231311796765012. ISSN   1872-3136.
70. Venturi S, Venturi M (2014). "Iodine, PUFAs and Iodolipids in Health and Disease: An Evolutionary Perspective". Human Evolution. 29 (1–3): 185–205.
71. Tamura K, Takayama S, Ishii T, Mawaribuchi S, Takamatsu N, Ito M (June 2015). "Apoptosis and differentiation of Xenopus tail-derived myoblasts by thyroid hormone". Journal of Molecular Endocrinology. 54 (3): 185–192. doi: 10.1530/JME-14-0327 . PMID   25791374.
72. Gelfand RA, Hutchinson-Williams KA, Bonde AA, Castellino P, Sherwin RS (June 1987). "Catabolic effects of thyroid hormone excess: the contribution of adrenergic activity to hypermetabolism and protein breakdown". Metabolism. 36 (6): 562–569. doi:10.1016/0026-0495(87)90168-5. PMID   2884552.
73. Stockigt, Jim R (January 2002). "Case finding and screening strategies for thyroid dysfunction". Clinica Chimica Acta. 315 (1–2): 111–124. doi:10.1016/s0009-8981(01)00715-x. ISSN   0009-8981. PMID   11728414.
74. Military Obstetrics & Gynecology > Thyroid Function Tests In turn citing: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, 1 May 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300
75. Polak M, Luton D (March 2014). "Fetal thyroïdology". Best Practice & Research. Clinical Endocrinology & Metabolism. 28 (2): 161–73. doi:10.1016/j.beem.2013.04.013. PMID   24629859.
76. Kirkegaard C, Faber J (January 1998). "The role of thyroid hormones in depression". European Journal of Endocrinology. 138 (1): 1–9. doi: 10.1530/eje.0.1380001 . PMID   9461307.
77. Dratman MB, Gordon JT (December 1996). "Thyroid hormones as neurotransmitters". Thyroid. 6 (6): 639–647. doi:10.1089/thy.1996.6.639. PMID   9001201.
78. Cappola, Anne R.; Desai, Akshay S.; Medici, Marco; Cooper, Lawton S.; Egan, Debra; Sopko, George; Fishman, Glenn I.; Goldman, Steven; Cooper, David S.; Mora, Samia; Kudenchuk, Peter J.; Hollenberg, Anthony N.; McDonald, Cheryl L.; Ladenson, Paul W.; Celi, Francesco S.; Dillman, Wolfgang; Ellervik, Christina; Gerdes, A. Martin; Ho, Carolyn; Iervasi, Giorgio; Lerman, Amir; Makino, Ayako; Ojamaa, Kaie; Peeters, Robin; Pingitore, Alessandro; Razvi, Salman; Wassner, Ari J. (2019). "Thyroid and Cardiovascular Disease". Circulation. 139 (25): 2892–2909. doi: 10.1161/CIRCULATIONAHA.118.036859 . PMC   6851449 . PMID   31081673.
79. Parry CH. Elements of Pathology and Therapeutics, Being the Outlines of a Work. Bath, England: R. Cruttwell, 1815.
80. "Myopathies associated with thyroid disease". MedLink Neurology. Retrieved 9 June 2023.
81. Rodolico, Carmelo; Bonanno, Carmen; Pugliese, Alessia; Nicocia, Giulia; Benvenga, Salvatore; Toscano, Antonio (1 September 2020). "Endocrine myopathies: clinical and histopathological features of the major forms". Acta Myologica. 39 (3): 130–135. doi:10.36185/2532-1900-017. ISSN   1128-2460. PMC   7711326 . PMID   33305169.
82. Celsing, F.; Blomstrand, E.; Melichna, J.; Terrados, N.; Clausen, N.; Lins, P. E.; Jansson, E. (April 1986). "Effect of hyperthyroidism on fibre-type composition, fibre area, glycogen content and enzyme activity in human skeletal muscle". Clinical Physiology (Oxford, England). 6 (2): 171–181. doi:10.1111/j.1475-097x.1986.tb00066.x. ISSN   0144-5979. PMID   2937605.
83. Sharma, Vikas; Borah, Papori; Basumatary, Lakshya J.; Das, Marami; Goswami, Munindra; Kayal, Ashok K. (2014). "Myopathies of endocrine disorders: A prospective clinical and biochemical study". Annals of Indian Academy of Neurology. 17 (3): 298–302. doi: 10.4103/0972-2327.138505 . ISSN   0972-2327. PMC   4162016 . PMID   25221399.
84. Fariduddin, Maria M.; Bansal, Nidhi (2023), "Hypothyroid Myopathy", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   30137798 , retrieved 9 June 2023
85. Dimitriadis, G D; Leighton, B; Parry-Billings, M; West, D; Newsholme, E A (15 January 1989). "Effects of hypothyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat". Biochemical Journal. 257 (2): 369–373. doi:10.1042/bj2570369. ISSN   0264-6021. PMC   1135589 . PMID   2649073.
86. Chea, Pauley; Rutan, Emily; Kousoubris, Philip D.; Freitag, Suzanne K. (1 January 2019), Small, Juan E.; Noujaim, Daniel L.; Ginat, Daniel T.; Kelly, Hillary R. (eds.), "39 - Thyroid-Associated Orbitopathy", Neuroradiology, Philadelphia: Elsevier, pp. 302–307, ISBN   978-0-323-44549-8 , retrieved 9 June 2023
87. Berbel P, Navarro D, Ausó E, Varea E, Rodríguez AE, Ballesta JJ, et al. (June 2010). "Role of late maternal thyroid hormones in cerebral cortex development: an experimental model for human prematurity". Cerebral Cortex. 20 (6): 1462–1475. doi:10.1093/cercor/bhp212. PMC   2871377 . PMID   19812240.
88. Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, de Rijke YB, et al. (January 2016). "Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study". The Lancet. Diabetes & Endocrinology. 4 (1): 35–43. doi:10.1016/s2213-8587(15)00327-7. hdl: 1765/79096 . PMID   26497402.
89. Szinnai G (March 2014). "Genetics of normal and abnormal thyroid development in humans". Best Practice & Research. Clinical Endocrinology & Metabolism. 28 (2): 133–150. doi:10.1016/j.beem.2013.08.005. PMID   24629857.
90. Spiegel C, Bestetti GE, Rossi GL, Blum JW (September 1993). "Normal circulating triiodothyronine concentrations are maintained despite severe hypothyroidism in growing pigs fed rapeseed presscake meal". The Journal of Nutrition. 123 (9): 1554–1561. doi: 10.1093/jn/123.9.1554 . PMID   8360780.